Difference between revisions of "Ibandronate (Boniva)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "[[Category:Drugs FDA" to "[[Category:FDA") |
||
| Line 24: | Line 24: | ||
[[Category:Bisphosphonates]] | [[Category:Bisphosphonates]] | ||
| − | [[Category: | + | [[Category:FDA approved in 2003]] |
Revision as of 19:09, 30 July 2018
General information
Class/mechanism: Bisphosphonate, inhibits osteoclast activity, dissolution of hydroxyapatite crystals, and bone resorption/turnover.[1][2][3][4][5]
Route: PO, IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Patient counseling information can be found on page 17-21 of the Ibandronate (Boniva) package insert[1]
- Patient counseling information can be found on page 18-21 of the Ibandronate injection (Boniva injection) package insert[3]
- Ibandronate (Boniva) patient drug information (UpToDate)[6]
Also known as
- Generic names: ibandronate sodium, ibandronic acid
- Brand names: Bandrobon, Bandrone, Bondenza, Bondronat, Bonviva, Femorel
References
- ↑ 1.0 1.1 1.2 Ibandronate (Boniva) package insert
- ↑ Ibandronate (Boniva) package insert (locally hosted backup)
- ↑ 3.0 3.1 Ibandronate injection (Boniva injection) package insert
- ↑ Ibandronate injection (Boniva injection) package insert (locally hosted backup)
- ↑ Boniva manufacturer's website
- ↑ Ibandronate (Boniva) patient drug information (UpToDate)